Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22321
Title: Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report.
Authors: Gunjur, Ashray;Chong, Geoffrey;Lim, Adeline;Lau, Eddie;Mitchell, Paul L R;John, Thomas;Arulananda, Surein
Affiliation: School of Cancer Medicine, La Trobe University, Heidelberg, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Radiology, Austin Health, Heidelberg, Victoria, Australia
Department of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Mar-2020
EDate: 2019-11-29
Citation: Clinical lung cancer 2020; 21(2): e57-e60
URI: http://ahro.austin.org.au/austinjspui/handle/1/22321
DOI: 10.1016/j.cllc.2019.11.014
ORCID: 0000-0001-9713-1872
PubMed URL: 31864906
Type: Journal Article
Subjects: Bevacizumab
EGFR-mutant
Gastro-oesophageal perforation
NSCLC
SABR
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.